Skip to Main Content

Paper Details

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Nature
2917
2020
COVID, COVID-, COVID-19, SARS, SARS-, SARS-CoV, SARS-CoV-2, cells, coronavirus disease 2019, disruption1,, druggable, host, human, human cells, human proteins, mRNA, people, severe acute respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus 2, sigma-1 and sigma-2 receptors
Animals, Antiviral Agents, Betacoronavirus, COVID-19, COVID-19 Drug Treatment, Chlorocebus aethiops, Cloning, Molecular, Coronavirus Infections, Drug Evaluation, Preclinical, Drug Repositioning, HEK293 Cells, Host-Pathogen Interactions, Humans, Immunity, Innate, Mass Spectrometry, Molecular Targeted Therapy, Pandemics, Pneumonia, Viral, Protein Binding, Protein Biosynthesis, Protein Domains, Protein Interaction Mapping, Protein Interaction Maps, Receptors, sigma, SARS-CoV-2, SKP Cullin F-Box Protein Ligases, Vero Cells, Viral Proteins
Author NameAffiliation
David E Gordon
David E GordonUniversity of California San Francisco
David E GordonJ. David Gladstone Institutes
David E GordonQuantitative Biosciences Institute (QBI), University of California San Francisco
Gwendolyn M Jang
Gwendolyn M JangUniversity of California San Francisco
Gwendolyn M JangJ. David Gladstone Institutes
Gwendolyn M JangQuantitative Biosciences Institute (QBI), University of California San Francisco
Mehdi Bouhaddou
Mehdi BouhaddouUniversity of California San Francisco
Mehdi BouhaddouJ. David Gladstone Institutes
Mehdi BouhaddouQuantitative Biosciences Institute (QBI), University of California San Francisco
Jiewei Xu
Jiewei XuUniversity of California San Francisco
Jiewei XuJ. David Gladstone Institutes
Jiewei XuQuantitative Biosciences Institute (QBI), University of California San Francisco
Kirsten Obernier (CM4AI)
Kirsten Obernier (CM4AI)University of California San Francisco
Kirsten Obernier (CM4AI)J. David Gladstone Institutes
Kirsten Obernier (CM4AI)Quantitative Biosciences Institute (QBI), University of California San Francisco
Kris M WhiteIcahn School of Medicine at Mount Sinai
Kris M WhiteGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Matthew J O'MearaUniversity of Michigan ann arbor
Veronica V RezeljCNRS UMR 9, Institut Pasteur
Jeffrey Z Guo
Jeffrey Z GuoUniversity of California San Francisco
Jeffrey Z GuoJ. David Gladstone Institutes
Jeffrey Z GuoQuantitative Biosciences Institute (QBI), University of California San Francisco
Danielle L Swaney
Danielle L SwaneyUniversity of California San Francisco
Danielle L SwaneyJ. David Gladstone Institutes
Danielle L SwaneyQuantitative Biosciences Institute (QBI), University of California San Francisco
Tia A Tummino
Tia A TumminoDepartment of Pharmaceutical Chemistry, University of California San Francisco
Tia A TumminoQuantitative Biosciences Institute (QBI), University of California San Francisco
Ruth H??ttenhain
Ruth H??ttenhainUniversity of California San Francisco
Ruth H??ttenhainJ. David Gladstone Institutes
Ruth H??ttenhainQuantitative Biosciences Institute (QBI), University of California San Francisco
Ruth H??ttenhain
Ruth H??ttenhainUniversity of California San Francisco
Ruth H??ttenhainJ. David Gladstone Institutes
Ruth H??ttenhainQuantitative Biosciences Institute (QBI), University of California San Francisco
Robyn M Kaake
Robyn M KaakeUniversity of California San Francisco
Robyn M KaakeJ. David Gladstone Institutes
Robyn M KaakeQuantitative Biosciences Institute (QBI), University of California San Francisco
Alicia L Richards
Alicia L RichardsUniversity of California San Francisco
Alicia L RichardsJ. David Gladstone Institutes
  • 1 - 50

Datasets